A randomized, single-blind, dose-rising, placebo-controlled, crossover study to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of Symlin [pramlintide] in adolescent subjects with type 1 diabetes mellitus

Trial Profile

A randomized, single-blind, dose-rising, placebo-controlled, crossover study to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of Symlin [pramlintide] in adolescent subjects with type 1 diabetes mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2013

At a glance

  • Drugs Pramlintide (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Sep 2009 Results published in the Journal of Pediatrics.
    • 07 Sep 2008 Results presented at the 44th Annual Meeting of the European Association for the Study of Diabetes
    • 01 Nov 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top